2016
DOI: 10.7150/jca.14425
|View full text |Cite
|
Sign up to set email alerts
|

An Investigation on a Novel Anti-tumor Fusion Peptide of FSH33-53-IIKK

Abstract: A novel fusion peptide FSH33-53-IIKK was designed and expected to combine the follicle stimulating hormone receptor (FSHR) targeting and tumor toxicity. In vitro and in vivo study showed the anti-tumor activity of FSH33-53-IIKK was enhanced compared to that of IIKK only. FSH33-53-IIKK could inhibit the growth of tumor via apoptosis and autophagy pathways. In summary, combining the tumor marker-target peptide and anti-tumor peptide together may be an efficient way to search for better anti-tumor candidates.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2020
2020
2022
2022

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 56 publications
(52 reference statements)
0
2
0
Order By: Relevance
“…For in vivo therapeutic studies, tumor cells (1 × 10 6 or 0.4 × 10 6 ) stably expressing red fluorescent protein were injected into dorsal flanks or tail vein of nude mice, respectively. One week later, mice were blindly randomized and treated by tail vein injection of synthesized cellpenetrating peptide [22] or lentivirus-mediated shRNA (1 × 10 7 plaque-forming units in 100 μl PBS), and imaged using In-Vivo Xtreme II small animal imaging system (Bruker Corporation, Billerica, MA).…”
Section: In Vivo Tumorigenesis and Aggressiveness Assaysmentioning
confidence: 99%
“…For in vivo therapeutic studies, tumor cells (1 × 10 6 or 0.4 × 10 6 ) stably expressing red fluorescent protein were injected into dorsal flanks or tail vein of nude mice, respectively. One week later, mice were blindly randomized and treated by tail vein injection of synthesized cellpenetrating peptide [22] or lentivirus-mediated shRNA (1 × 10 7 plaque-forming units in 100 μl PBS), and imaged using In-Vivo Xtreme II small animal imaging system (Bruker Corporation, Billerica, MA).…”
Section: In Vivo Tumorigenesis and Aggressiveness Assaysmentioning
confidence: 99%
“…5) Rare earths are called as the "vitamins" for metals, 6) which means a small amount of rare earths can improve the properties. Rare earth La and Ce were selected as additives into NiCr filler metals, 7) 0.1% La and 0.05% Ce can enhance the wettability of filler metals with base material, the brazing performance can also be improved, the good interface can be fabricated by this filler metal and infiltration brazing technology. C was added into NiCr filler metal to modify the property and microstructure, 8) 1.0% C can enhance the wettability, can react with Cr to form the carbide, in which part of Cr 3 C 2 can grow in nucleus on the diamond surface, Cr 7 C 3 can be formed in brazed joints, the micro-hardness of the brazed joints decreases from 630 HV0.2 to 580 HV0.2.…”
Section: Introductionmentioning
confidence: 99%